Product Description
Riluzole, a benzothiazole, affects neurons by 3 mechanisms: by inhibiting excitatory amino acid release, inhibiting events following stimulation of excitatory amino acid receptors and stabilising the inactivated state of voltage-dependent sodium channels. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/8891467/)
Mechanisms of Action: Sodium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis
Known Adverse Events: Abdominal Pain | Dizziness | Pain Unspecified | Asthenia | Hypertension
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: France, Italy
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Amyotrophic Lateral Sclerosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TRIALS Protocol | P2 |
Active, not recruiting |
Amyotrophic Lateral Sclerosis |
2025-01-01 |
32% |
| TRIALS Protocol | P2 |
Active, not recruiting |
Amyotrophic Lateral Sclerosis |
2025-01-01 |
32% |